$18.5 million in extension funding will support clinical pipeline of microbiome-derived product candidates CAMBRIDGE, Mass., May 13, 2019-- Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, has raised an additional $18.5 million as an extension of its Series C financing, bringing the total for the round to $45.5 million.